The ECPM advisory board is composed of key stakeholders in medicines development representing academia, the pharmaceutical industry, regulatory authorities, the ECPM teaching faculty as well as representatives from the EUCOR medical schools and other partner universities.
The advisory board meets annually to review the outcome of the last year and advises on new strategies for the future.
The aim of the advisory board is to ensure that ECPM training and research is on trend with what is currently relevant in the industry, including, new developments, needs and trends. The advisory board members represent a critical sounding board and a think tank helping ECPM to evolve offerings to meet customer and market needs.
Members of the Advisory Board
Dr. Ruth Amstein, Zurich Heart House
Dr. Gerd Antes, Albert-Ludwigs-University
Mr. Urs Brügger, University of Applied Science, Bern
Dr. med. Brigitte Franke-Bray FFPM, IFAPP, Muttenz
Dr. Rolf Heusser, National Institute for Cancer Epidemiology and Registration (NICER), Zurich
Dr. Martin Liechti, University of Basel
Dr. Detlef Niese, former Novartis Pharma AG, University of Basel
Prof. Martin Schumacher, Albert-Ludwigs-University, Freiburg i. Br.
Mr. Richard Bergström, SICPA
PD Dr. Patricia Blank, Roche Diagnostics
Mr. Oliver Bleck, Roche Pharma (Schweiz) AG
Dr. Martine Clozel, Idorsia Pharmaceuticals Ltd.
Mr. Thomas Cueni, IFPMA
Dr. David Ebsworth, former Vifor Pharma AG
Dr. Djordje Filipovic, Novartis Pharma AG
Dr. Anthony Man, Novartis Pharma AG
Dr. Oliver Nayler, Idorsia Pharmaceuticals Ltd.
Dr. Claus Bolte, Swissmedic